local_hospital

Savon Psykiatripalvelu Oy

Address
Asemakatu 46b 23, 70110 Kuopio, Finland

Savon Psykiatripalvelu Oy - Psychiatric Research Center

Savon Psykiatripalvelu Oy is a specialized psychiatric research facility dedicated to advancing the understanding and treatment of mental health disorders. The center focuses on conducting rigorous clinical trials to evaluate innovative therapeutic interventions for patients experiencing various psychiatric conditions.

  • Generalized Anxiety Disorder treatment evaluation and novel pharmacological interventions
  • Assessment of safety and efficacy profiles for emerging psychiatric medications
  • Clinical outcome measurement using validated psychiatric rating scales

The center's research expertise includes the investigation of SEP-363856, a novel therapeutic agent for Generalized Anxiety Disorder (GAD), utilizing standardized assessment tools such as the Hamilton Anxiety Rating Scale (HAM-A). Through carefully designed placebo-controlled studies with flexible dosing protocols, Savon Psykiatripalvelu Oy contributes valuable data to the development of next-generation treatments that may improve outcomes for adults living with anxiety disorders.

Site Overview

assignment
6
connected trials
corporate_fare
4
sponsors
science
4
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
6
Total trials linked
Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
4
Sponsors (total)
4
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +1 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 107 other sites in Finland

description
Trial volume
6
Outperforms 74% of sites
public
Therapeutic diversity
1areas
Outperforms 0% of sites
groups
Sponsor diversity
4sponsors
Outperforms 70% of sites

Therapeutic Area Benchmark — Finland

Select a therapeutic area to compare against other sites in Finland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Finland

Market Share

Country: Finland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Savon Psykiatripalvelu Oy

lock Showing 1 of 6 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety DisorderOtsuka Pharmaceutical Development & Commercialization Inc.Phase IVNot RecruitingSep 2023Sep 2025

IMP list

lock Showing 1 of 4 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE2Unknown2025-08-282025-10-07

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.